{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:08:28Z","timestamp":1790960908159,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Infections remain a major concern following bispecific antibody therapy but are not well described in pivotal trials. We present the first well-documented case of a classic but rare opportunistic infection, disseminated Mycobacterium avium complex, in a patient receiving bispecific antibody therapy.<\/jats:p>","DOI":"10.1093\/ofid\/ofae460","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:03:57Z","timestamp":1723143837000},"source":"Crossref","is-referenced-by-count":3,"title":["Disseminated <i>Mycobacterium avium<\/i> Complex Infection Following CD3\/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S","family":"Little","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Stem Cell Transplant and Cellular Therapy, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio M","family":"Hurtado","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Boire","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Pathology, Brigham and Women's Hospital , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Stem Cell Transplant and Cellular Therapy, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro C","family":"Laga","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Pathology, Brigham and Women's Hospital , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W","family":"Silk","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Stem Cell Transplant and Cellular Therapy, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2024092714512317600_ofae460-B1","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024092714512317600_ofae460-B2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"2024092714512317600_ofae460-B3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2024092714512317600_ofae460-B4","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"2024092714512317600_ofae460-B5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024092714512317600_ofae460-B6","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"2024092714512317600_ofae460-B7","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"key":"2024092714512317600_ofae460-B8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10096-011-1407-7","article-title":"Mycobacterial infections in adult patients with hematological malignancy","volume":"31","author":"Chen","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024092714512317600_ofae460-B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/clinids\/17.1.7","article-title":"Mycobacterium avium complex infection and AIDS: advances in theory and practice","volume":"17","author":"Benson","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2024092714512317600_ofae460-B10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2024092714512317600_ofae460-B11","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"2024092714512317600_ofae460-B12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and Intergroupe Francophone du My\u00e9lome","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2024092714512317600_ofae460-B13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae460\/58775514\/ofae460.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae460\/59361511\/ofae460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae460\/59361511\/ofae460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:51:38Z","timestamp":1727448698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae460\/7729970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae460","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,8]]},"article-number":"ofae460"}}